Arena (ARNA) Clears Final BELVIQ Marketing Hurdle; Could Make U.S. Debut in June
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals' (Nasdaq: ARNA) BELVIQ might make its U.S. debut sooner than expected.
The U.S. DEA put BELVIQ on Schedule 4 today, which is the final hurdle ahead of marketing the drug. (For the DEA statement, click here.)
Following tomorrow's publication in the Federal Register, the ruling will be effective within 30 days.
Arena is up over 7 percent Tuesday. The news comes as the company notified the European Medicines Agency last week that it was withdrawing the BELVIQ Marketing Authorization Application (MAA) in the European Union.
Lower on the session is peer VIVUS, Inc. (Nasdaq: VVUS).
The U.S. DEA put BELVIQ on Schedule 4 today, which is the final hurdle ahead of marketing the drug. (For the DEA statement, click here.)
Following tomorrow's publication in the Federal Register, the ruling will be effective within 30 days.
Arena is up over 7 percent Tuesday. The news comes as the company notified the European Medicines Agency last week that it was withdrawing the BELVIQ Marketing Authorization Application (MAA) in the European Union.
Lower on the session is peer VIVUS, Inc. (Nasdaq: VVUS).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Anthropic hires Google chip veteran as it pushed into hardware - Bloomberg
- Trump admin taps former JPMorgan Chase exec Matt Zames to advise social security agency - CNBC
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
